Abstract: The machine comprises a solid matrix (1), a deformable body (2) joined to the surface of said matrix (1), a shaping mould (3) and a securing system system (5) for the fibre structure (4). The matrix (1) is a solid element having a functional face, the geometry of which depends on the part to be manufactured. The deformable body (2) has an initial geometry that depends on the geometry to be given to the fibre structure (4). The shaping mould (3) has the geometry to be given to the fibre structure (4) during the process of adaptation to the shaping mould (3), and the shaping mould (3) is located such that the deformable body (2) is located between said shaping mould (3) and the matrix (1).

Abstract: The machine comprises a solid matrix (1), a deformable body (2) joined to the surface of said matrix (1), a shaping mould (3) and a securing system system (5) for the fibre structure (4). The matrix (1) is a solid element having a functional face, the geometry of which depends on the part to be manufactured. The deformable body (2) has an initial geometry that depends on the geometry to be given to the fibre structure (4). The shaping mould (3) has the geometry to be given to the fibre structure (4) during the process of adaptation to the shaping mould (3), and the shaping mould (3) is located such that the deformable body (2) is located between said shaping mould (3) and the matrix (1).

Abstract: In various embodiments, the present invention relates to a topical pharmaceutical composition for treating a skin condition, comprising a combination of agents, wherein the combination includes: a) one or more antimicrobial compounds; b) one or more trace elements; c) one or more tissue reconstruction elements; and d) one or more analgesics, and a pharmaceutically-acceptable carrier. In certain embodiments, the invention relates to a topical pharmaceutical composition comprising silver sulfadiazine, zinc oxide, lidocaine, bacitracin, neomycin (e.g., neomycin sulfate), polymixin B (e.g., polymixin B sulfate), vitamin E and Coenzyme Q10. In other embodiments, the invention relates to a method of treating a skin condition in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of topical pharmaceutical composition of the invention.

Abstract: In various embodiments, the present invention relates to a topical pharmaceutical composition for treating a skin condition, comprising a combination of agents, wherein the combination includes: a) one or more antimicrobial compounds; b) one or more trace elements; c) one or more tissue reconstruction elements; and d) one or more analgesics, and a pharmaceutically-acceptable carrier. In certain embodiments, the invention relates to a topical pharmaceutical composition comprising silver sulfadiazine, zinc oxide, lidocaine, bacitracin, neomycin (e.g., neomycin sulfate), polymixin B (e.g., polymixin B sulfate), vitamin E and Coenzyme Q10. In other embodiments, the invention relates to a method of treating a skin condition in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of topical pharmaceutical composition of the invention.

Abstract: A method for the shipment and preservation of organ-derived cells in which the shipping medium is in a firm, substantially congealed state at ambient and chilled temperatures, but becomes substantially fluid upon reaching body temperature. The medium in its fluid state can be poured over cultured cells or tissue slices or used to suspend isolated cells and then can be chilled to reach its congealed state for shipment.

Abstract: A medium for the shipment and preservation of organ-derived cells and method for its use. The shipping medium is in a firm, substantially semi-solid state at ambient and chilled temperatures, but becomes substantially fluid upon reaching body temperature. The medium in its fluid state can be poured over cultured cells or tissue slices or used to suspend isolated cells and then can be chilled to reach its semi-solid state for shipment. The firm, semi-solid nature of the medium and the presence of various components preserves organ-derived cells for a longer period of time during shipping than the preservation time achieved by using conventional liquid medium, better protects the organ-derived cells during shipment, effectively eliminates spillage during transport, and is easily used by researchers who supply preserved organ-derived cells as well as by researchers who receive the preserved organ-derived cells for experimentation or research.